Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.

Citation

• Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Sternberg, C. N., Logothetis, C., . . . Rathkopf, D. E. (2015). Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.. Journal of Clinical Oncology, 33(7_suppl), 142. doi:10.1200/jco.2015.33.7_suppl.142

Digital Object Identifier (doi)

• 10.1200/jco.2015.33.7_suppl.142

Web Of Science Accession Number

Start Page

• 142

End Page

• 142

Volume

• 33

Issue

• 7_suppl

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2015

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Sternberg, C. N., Logothetis, C., . . . Rathkopf, D. E. (2015). Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.. Journal of Clinical Oncology, 33(7_suppl), 142. doi:10.1200/jco.2015.33.7_suppl.142

Digital Object Identifier (doi)

• 10.1200/jco.2015.33.7_suppl.142

Web Of Science Accession Number

Start Page

• 142

End Page

• 142

Volume

• 33

Issue

• 7_suppl